The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes
Open accessAbstract
While lymphocytopenia is a common characteristic of patients infected by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the mechanisms responsible for this depletion are unclear. Through careful inspection of the spleens and lymph nodes (LNs) from six cases with postmortem examinations, we observed that SARS-CoV-2 could directly infect secondary lymphoid organs to induce cell death. Immunohistochemistry demonstrated ACE2 (angiotensin-converting enzyme 2), the potential receptor of SARS-CoV-2, expresses on tissue-resident CD169 + macrophages in spleens and LNs. Immunofluorescent staining confirmed that viral nucleocaspid protein (NP) can be found in ACE2 + cells, CD169 + macrophages, but not in CD3 + T cells or B220 + B cells in spleens and LNs. SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions. Moreover, in situ TUNEL staining illustrated that viral infection leads to severe lymphocyte apoptosis, which might be mediated by viral antigens inducing Fas upregulation. Furthermore, SARS-CoV-2 also triggers macrophages to produce IL-6, a proinflammatory cytokine that directly promotes lymphocyte necrosis. Collectively, these results demonstrate that SARS-CoV-2 directly neutralizes human spleens and LNs through infecting tissue-resident CD169 + macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationLu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Self-citationStructure and function of the spleen
Mebius, R. E., & Kraal, G. (2005) · Nature Reviews Immunology · doi:10.1038/nri1669 · Cited by 2,238
Xu, X.-W., Wu, X.-X., Jiang, X.-G., Xu, K.-J., Ying, L.-J., Ma, C.-L., Li, S.-B., Wang, H.-Y., Zhang, S., Gao, H.-N., et al. (2020) · BMJ · doi:10.1136/bmj.m606 · Cited by 2,046
CD95's deadly mission in the immune system
Krammer, P. H. (2000) · Nature · doi:10.1038/35037728 · Cited by 1,717
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
TNF and ROS crosstalk in inflammation
Blaser, H., Dostert, C., Mak, T. W., & Brenner, D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.12.002 · Cited by 1,008 · cited 2×
“In addition to antigen persistence stimulation, some proinflammatory cytokines like IL-6, TNF-α and IFN-γ can also can mediate cellular apoptosis and necrosis.(20,21) We focused here on IL-6 because it contributes to host defense against to several kinds of pathogen infections.”
BackgroundThe many roles of FAS receptor signaling in the immune system
Strasser, A., Jost, P. J., & Nagata, S. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.001 · Cited by 968 · cited 2×
“10 / 18 The presence of viral antigens would activate T cells and B cells in spleen and LNs, and thus lead to Fas and FasL mediated AICD.17,19 Although the level of FasL in spleens and LNs is similar in tissues from postmortem and age-match normal healthy controls, the expression of Fas is dramatically higher in virus…”
BackgroundFas ligand mediates activation-induced cell death in human T lymphocytes.
Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., & Lynch, D. H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.71 · Cited by 934
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection
Diao, B., Wang, C., Wang, R., Feng, Z., Zhang, J., Yang, H., Tan, Y., Wang, H., Wang, C., Liu, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22781-1 · Cited by 900
Self-citationLe, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 1×
“Tocilizumab, a humanized anti-IL-6 receptor antibody, has been developed and approved for the treatment of rheumatoid arthritis (RA).(30,31) Tocilizumab has also been shown to be effective against cytokine release syndrome resulting from CAR-T cell infusion against B cell acute lymphoblastic leukemia.”
Junt, T., Moseman, E. A., Iannacone, M., Massberg, S., Lang, P. A., Boes, M., Fink, K., Henrickson, S. E., Shayakhmetov, D. M., Di Paolo, N. C., et al. (2007) · Nature · doi:10.1038/nature06287 · Cited by 846 · cited 10×
“Here ACE2 expression in normal kidneys were used as positive controls (Figure 1E), and sections without primary antibodies were used as isotype controls (Figure 1F), demonstrating ACE2+ cells are positions in human spleens and LNs.”
BackgroundInfluentialThe clinical pathology of severe acute respiratory syndrome (SARS): a report from China
Ding, Y., Wang, H., Shen, H., Li, Z., Geng, J., Han, H., Cai, J., Li, X., Kang, W., Weng, D., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1440 · Cited by 765
Wang, W., Ye, L., Ye, L., Li, B., Gao, B., Zeng, Y., Kong, L., Fang, X., Zheng, H., Wu, Z., et al. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.007 · Cited by 247
Aichele, P., Zinke, J., Grode, L., Schwendener, R. A., Kaufmann, S. H. E., & Seiler, P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1148 · Cited by 243
Dosch, S. F., Mahajan, S. D., & Collins, A. R. (2009) · Virus Research · doi:10.1016/j.virusres.2009.01.005 · Cited by 228
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207628 · Cited by 194 · cited 1×
“Tocilizumab, a humanized anti-IL-6 receptor antibody, has been developed and approved for the treatment of rheumatoid arthritis (RA).(30,31) Tocilizumab has also been shown to be effective against cytokine release syndrome resulting from CAR-T cell infusion against B cell acute lymphoblastic leukemia.”
Backer, R., Schwandt, T., Greuter, M., Oosting, M., Jüngerkes, F., Tüting, T., Boon, L., O’Toole, T., Kraal, G., Limmer, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909541107 · Cited by 191
Tamburini, B. A., Burchill, M. A., & Kedl, R. M. (2014) · Nature Communications · doi:10.1038/ncomms4989 · Cited by 153 · cited 1×
“8, 9 These macrophages present viral antigens to activate specific T cells, to induce activation, clonal proliferation, and subsequent killing of infected target cells through secretion of perforin, granzyme B, and interferon-γ etc.”
Backgroundvan Dinther, D., Veninga, H., Iborra, S., Borg, E. G. F., Hoogterp, L., Olesek, K., Beijer, M. R., Schetters, S. T. T., Kalay, H., García-Vallejo, J. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.021 · Cited by 148
Bernhard, C., Ried, C., Kochanek, S., & Brocker, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423356112 · Cited by 123
Peripheral tissue surveillance and residency by memory T cells
Gebhardt, T., Mueller, S. N., Heath, W. R., & Carbone, F. R. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.08.008 · Cited by 101
Subcapsular Sinus Macrophages: The Seat of Innate and Adaptive Memory in Murine Lymph Nodes
Moran, I., Grootveld, A. K., Nguyen, A., & Phan, T. G. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.004 · Cited by 95
The spleen as a target in severe acute respiratory syndrome
Zhan, J., Deng, R., Tang, J., Zhang, B., Tang, Y., Wang, J. K., Li, F., Anderson, V., McNutt, M. A., & Gu, J. (2006) · The FASEB Journal · doi:10.1096/fj.06-6324com · Cited by 50
Cited by
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
“Serum levels of TNF, IL-6 and IL-10 negatively correlated with T cell numbers 20 .”
BackgroundInfluentialImmunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1783198 · Cited by 1,514
Self-citationPeng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0782-6 · Cited by 1,179
“incomplete and sometimes conflicting[3, 11, 12, 13, 14].”
Self-citationCytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094
“Another team of Chen and his colleagues studied themechanisms for lymphopenia (49).”
Background
Metadata
- Authors
- Feng, Z., Diao, B., Wang, R., Wang, G., Wang, C., Tan, Y., Liu, L., Wang, C., Liu, Y., Liu, Y., Yuan, Z., Ren, L., Wu, Y., & Chen, Y.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2020-03-31
- OpenAlex
- W3014799733
- Cited by
- 362
- References
- 32
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.